Company news
News Center
News center
202606-03
Welcome to Shanghai CPHI Exhibition!
CPHI China 2026 – Shanghai
Lunarsun warmly welcomes you to the World Pharmaceutical Ingredients Exhibition!
Date: June 16–18, 2026
Address: Shanghai New International Expo Centre (SNIEC), Pudong
Booth No.: W4Q02
We sincerely invite both new and existing partners to visit us for business discussions!
202605-20
Moxifloxacin Hydrochloride Tablets Approved for Marketing by NMPA
Recently, Moxifloxacin Hydrochloride Tablets (National Drug Approval No. H20264233), developed and held by our wholly-owned subsidiary Chongqing Saintsun Pharmaceutical Technology Co., Ltd., have been officially approved for marketing by the National Medical Products Administration (NMPA). Moxifloxacin Hydrochloride Tablets represent another approved antibiotic product following Tigecycline for Injection and Moxifloxacin Hydrochloride and Sodium Chloride Injection.
202604-16
Tigecycline for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection began commercial launch
The two antibiotic products, Tigecycline for Injection and Moxifloxacin Hydrochloride Sodium Chloride Injection, began commercial production and were approved for sale this year. They are the first two of formulation products that our wholly-owned subsidiary Chongqing Saintsun has developed, commercially produced and initiated the marketing.
202506-06
Welcome to Shanghai CPHI Exhibition!
CPHI China 2025 – Shanghai
Lunarsun warmly welcomes you to the World Pharmaceutical Ingredients Exhibition!
Date: June 24–26, 2025
Address: Shanghai New International Expo Centre (SNIEC), Pudong
Booth No.: W4 Q02
We sincerely invite both new and existing partners to visit us for business discussions!
202412-26
Our new website has launched on December 26, 2024.
Our website have a revision and upgrade. The new one is launched on December 26,2024.
202409-14
Congratulations to Lunarsun Pharmaceuticals on the National Medical Products Administration approval of Tigecycline for Injection!
Lunarsun Pharma's Tigecycline for Injection has officially been approved for marketing.
Approval Number: H20244853
We welcome your inquiries and cooperation!
202408-05
Congratulations to Lunarsum Pharmaceuticals on the National Medical Products Administration Approval of Famotidine Injection!
Lunarsum Pharma's Famotidine Injection has been officially approved for marketing.
Approval Number: H20244490
We welcome your inquiries and cooperation!
202401-18
Congratulations to Lunarsun on the Successful Status Upgrade of Mirabegron to “Active”!
Beijing Lunarsun Pharma is proud to announce that the imported API Mirabegron was successfully approved for turning into “Active ”on January 18, 2024.
Registration Number: Y20210000398
We warmly invite pharmaceutical manufacturers to reach out for collaboration opportunities.
